Development of new predictive markers for endocrine therapy and resistance in breast cancer

References

• Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569–83
   PubMed Web of Science ®Google Scholar
• Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474–81
   PubMed Web of Science ®Google Scholar
• Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, et al. Relationship between quantitative estrogen and progesterone receptor expression and Human Epidermal Growth Factor Receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 2008; Epub ahead of print.
   Google Scholar
• Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1–98. J Clin Oncol 2007; 25: 3846–52
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del CB, Henriksen KL, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: Supplementary results from the BIG 1–98 randomised trial. Lancet Oncol 2008; 9: 23–8
   PubMed Web of Science ®Google Scholar
• Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976; 36: 4595–601
   PubMed Web of Science ®Google Scholar
• Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004; 10: 331S–6S
   PubMed Web of Science ®Google Scholar
• Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003; 21: 1973–9
   PubMed Web of Science ®Google Scholar
• Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144: 4562–74
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM, et al. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord 2007; 8: 241–53
   PubMedGoogle Scholar
• Lykkesfeldt AE, Madsen MW, Briand P. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Cancer Res 1994; 54: 1587–95
   PubMed Web of Science ®Google Scholar
• Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29–30
   PubMed Web of Science ®Google Scholar
• Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, et al. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995; 55: 3331–8
   PubMed Web of Science ®Google Scholar
• Frogne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 2005; 12: 599–614
   PubMed Web of Science ®Google Scholar
• Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG, Stenvang J. Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther 2007; 6: 1869–76
   PubMed Web of Science ®Google Scholar
• Sasano H, Anderson TJ, Silverberg SG, Santen RJ, Conway M, Edwards DP, et al. The validation of new aromatase monoclonal antibodies for immunohistochemistry–a correlation with biochemical activities in 46 cases of breast cancer. J Steroid Biochem Mol Biol 2005; 95: 35–9
   PubMed Web of Science ®Google Scholar
• Sonne-Hansen K, Lykkesfeldt AE. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. J Steroid Biochem Mol Biol 2005; 93: 25–34
   PubMedGoogle Scholar
• Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O. Model systems: Mechanisms involved in the loss of sensitivity to letrozole. J Steroid Biochem Mol Biol 2005; 95: 41–8
   PubMed Web of Science ®Google Scholar
• Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003; 278: 30458–68
   PubMed Web of Science ®Google Scholar
• Johnston SR, Martin LA, Head J, Smith I, Dowsett M. Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 2005; 95: 173–81
   PubMed Web of Science ®Google Scholar
• Knoop AS, Bentzen S, Nielsen MM, Rasmussen BB, Rose C. Value of Epidermal Growth Factor Receptor, HER2, p53 and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001; 19: 3376–84
   PubMed Web of Science ®Google Scholar
• Duffy MJ. Predictive markers in breast and other cancers: A review. Clin Chem 2005; 51: 494–503
   PubMed Web of Science ®Google Scholar
• Lyng MB, Laenkholm AV, Vach W, Pallisgaard N, Knoop A, Ditzel HJ. Predictive gene expression profile of breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2007; 106: S167
   Google Scholar
• Wurtz SO, Henriksen KL, Lykkesfeldt A, Celis J, Brunner NA. Integration af nye og fremtidige biologiske markører i behandling af cancer mammae. Ugeskr Laeger 2007; 169: 2999–3003
   PubMedGoogle Scholar
• Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007; 99: 167–70
   PubMed Web of Science ®Google Scholar